Boeszoermenyi, Andras http://orcid.org/0000-0001-9810-7241
Bernaleau, Léa
Chen, Xudong
Kartnig, Felix
Xie, Min
Zhang, Haobo http://orcid.org/0000-0002-4112-1883
Zhang, Sensen
Delacrétaz, Maeva http://orcid.org/0009-0003-4154-5277
Koren, Anna
Hopp, Ann-Katrin
Dvorak, Vojtech
Kubicek, Stefan http://orcid.org/0000-0003-0855-8343
Aletaha, Daniel http://orcid.org/0000-0003-2108-0030
Yang, Maojun
Rebsamen, Manuele http://orcid.org/0000-0001-6172-4211
Heinz, Leonhard X. http://orcid.org/0000-0002-6921-1493
Superti-Furga, Giulio http://orcid.org/0000-0002-0570-1768
Article History
Received: 24 March 2023
Accepted: 29 September 2023
First Online: 20 October 2023
Competing interests
: CeMM and the Medical University of Vienna are the applicants of European priority patent applications (EP 22 203 423.3, EP 22 203 422.5, EP 22 203 421.7, status: filed), with inventors A.B., M.R., L.H. and G.S.-F, covering small-molecule modulators of TASL and their medical use. G.S.-F. and S.K. are co-founders and own shares of Proxygen GmbH and Solgate GmbH, an SLC-focused company. D.A. received grants, speaker fees, or consultancy fees from Abbvie, Gilead, Galapagos, Eli Lilly, Janssen, Merck, Novartis. The other authors declare no competing interests.